Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions

2 references·16 citing·38 second hop

FromToDepth

this work references cited by second hop

References

2018The Patient Protection and Affordable Care Act863 cited
2008Celebrating the New76 cited

Cited by

2015Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study216 cited
2018Financial toxicity and implications for cancer care in the era of molecular and immune therapies214 cited
2018Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance189 cited
2019Impact of Cancer on Employment166 cited
2014Self-Reported Financial Burden and Satisfaction With Care Among Patients With Cancer159 cited
2019Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation151 cited
2017Financial Burden in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study125 cited
2013Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer113 cited
2015Identifying cancer patients who alter care or lifestyle due to treatment‐related financial distress88 cited
2019Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer88 cited
2017Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States84 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2022Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions82 cited

2020Potential impact of the COVID ‐19 pandemic on financial toxicity in cancer survivors72 cited

2013Cancer Patients’ Trade-offs Among Efficacy, Toxicity, and Out-of-Pocket Cost in the Curative and Noncurative Setting67 cited

2022Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy59 cited

2011Benchmarks for Value in Cancer Care: An Analysis of a Large Commercial Population58 cited